AndrewJonCutlerMD

Psychiatry • Lakewood Ranch, FL

Physician

Join to view full profile

Dr. Cutler is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Cutler's full profile

Already have an account?

Office
8429 Lorraine Rd.
#350
Lakewood Ranch, FL 34202
Phone+1 941-356-0116

Education & Training

University of Virginia Medical CenterResidency, Internal Medicine, 1989 - 1994
University of Virginia School of MedicineClass of 1989

Certifications & Licensure

FL State Medical License 1995 - 2026
AZ State Medical License 2011 - 2017
VA State Medical License 1990 - 2004
PA State Medical License 1992 - 2002
IL State Medical License 1994 - 1996
American Board of Psychiatry and Neurology Psychiatry

Clinical Trials

Olanzapine Given in Combination With Zonisamide SR to Prevent Weight Gain in Schizophrenic Subjects Start of enrollment: 2008 Sep 01
Terminated
Phase 2
A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder Start of enrollment: 2010 Jun 01
Completed
Phase 3
Major Depressive Disorder With Mixed Features - Extension Start of enrollment: 2011 Sep 01
Completed
Phase 3
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) Start of enrollment: 2011 Dec 01
Completed
Phase 2
Study of Flexible Doses of the Triple Reuptake Inhibitor EB-1020 Sustained Release (SR) in the Treatment of Adult Males With Attention-Deficit Hyperactivity Disorder Start of enrollment: 2013 Oct 03
Completed
Phase 2
Cognitive ADHD Videogame Exploratory Study Start of enrollment: 2013 Sep 01
Completed
Not Applicable
PRC-063 in Adolescent ADHD Start of enrollment: 2014 Apr 01
Completed
Phase 3
Open-label Safety Study in Adults With ADHD Start of enrollment: 2014 Jun 01
Completed
Phase 3
Long-Term Safety of PRC-063 in Adolescents and Adults With ADHD Start of enrollment: 2014 May 01
Completed
Phase 3
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD) Start of enrollment: 2015 Jun 18
Completed
Phase 3
A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Classroom Setting Start of enrollment: 2015 Jul 01
Completed
Phase 3
A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Naturalistic Setting Start of enrollment: 2015 Aug 01
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

9 citations
Good, better, best: clinical scenarios for the use of L-methylfolate in patients with MDD.
Rakesh Jain, Sloan Manning, Andrew J. Cutler, Andrew J. Cutler
CNS Spectrums. 2020-12-01
7 citations
The efficacy of lumateperone on symptoms of depression in bipolar I and bipolar II disorder: Secondary and post hoc analyses.
Roger S McIntyre, Suresh Durgam, Susan G Kozauer, Richard Chen, Jason Huo
European Neuropsychopharmacology. 2023-03-01
51 citations
A Phase III, Randomized, Placebo-controlled Trial to Assess the Efficacy and Safety of Once-daily SPN-812 (Viloxazine Extended-release) in the Treatment of Attention-d...
Azmi Nasser, Tesfaye Liranso, Toyin Adewole, Nicholas Fry, Joseph T. Hull
Clinical Therapeutics. 2020-07-25

Lectures

2011 NEI Global Psychopharmacology Congress
Neuroscience Education Institute, Colorado Springs, Colorado - 11/10/2011

Press Mentions

Azstarys Outperforms Placebo for Improving ADHD Symptoms in ChildrenNovember 4th, 2021
ADHD Comorbidities Complicate Diagnosis of the DisorderJune 3rd, 2021
New ADHD Medications Allow for More Personalized Treatment PlansMay 25th, 2021
Join now to see all

AndrewJonCutlerMD

Dr. Cutler is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Press Mentions

Viewing the full profile is available to verified healthcare professionals only.